false2022-06-302022Q20001637890--12-31The operating loss arises from the Company’s loss for the period before deduction of financial income, Financial expenses and Income taxes. The purpose of this measure by Management is to identify the Company’s results in connection with its operating activities.For information on voluntary change in accounting policy, see note 5.2.16 of the 2021 Annual Report.Other reserves include Share-base payment reserve, Other equity reserve from conversion of convertible loan in 2013 and Currency Translation Difference.Pursuant to Belgian law (“CCA”), the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of the Company’s standalone non-consolidated statutory financial statements of Celyad Oncology SA prepared under Belgian GAAP, and not on the basis of IFRS consolidated financial statements. For more information, see note 2.5.12.Interests on leases are presented as operating cash flow. 0001637890 2022-06-30 0001637890 2021-12-31 0001637890 2021-01-01 2021-06-30 0001637890 2022-01-01 2022-06-30 0001637890 2017-12-31 0001637890 2021-01-01 2021-12-31 0001637890 2015-01-01 2015-12-31 0001637890 2021-07-01 2021-12-31 0001637890 2020-12-31 0001637890 2021-06-30 0001637890 cyad:MesoblastLicenceAgreementMember 2022-06-30 0001637890 cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember ifrs-full:Level1OfFairValueHierarchyMember 2022-06-30 0001637890 ifrs-full:Level2OfFairValueHierarchyMember cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2022-06-30 0001637890 ifrs-full:Level1OfFairValueHierarchyMember 2022-06-30 0001637890 ifrs-full:Level2OfFairValueHierarchyMember 2022-06-30 0001637890 ifrs-full:Level3OfFairValueHierarchyMember 2022-06-30 0001637890 cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2022-06-30 0001637890 cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember ifrs-full:Level3OfFairValueHierarchyMember 2022-06-30 0001637890 ifrs-full:AtFairValueMember 2022-06-30 0001637890 cyad:WalloonRegionMember 2022-06-30 0001637890 ifrs-full:OtherIntangibleAssetsMember 2022-06-30 0001637890 cyad:PatentsAndLicencesMember 2022-06-30 0001637890 ifrs-full:GoodwillMember 2022-06-30 0001637890 cyad:CathezDevelopmentCostsMember 2022-06-30 0001637890 cyad:OnCyteIprdMember 2022-06-30 0001637890 cyad:RecoverableCashAdvancesMember 2022-06-30 0001637890 cyad:CeldaraMedicalMember 2022-06-30 0001637890 ifrs-full:ContingentConsiderationMember 2022-06-30 0001637890 ifrs-full:CapitalRedemptionReserveMember 2022-06-30 0001637890 cyad:WalloonRegionMember cyad:RecoverableCashAdvancesMember cyad:RegionalGovernmentMember 2022-06-30 0001637890 cyad:WalloonRegionMember cyad:OtherGrantsMember cyad:FederalBelgianInstituteForHealthInsuranceInamiMember 2022-06-30 0001637890 cyad:MesoblastLicenceAgreementMember 2021-12-31 0001637890 ifrs-full:Level1OfFairValueHierarchyMember 2021-12-31 0001637890 ifrs-full:Level2OfFairValueHierarchyMember 2021-12-31 0001637890 ifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001637890 cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2021-12-31 0001637890 ifrs-full:Level3OfFairValueHierarchyMember cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2021-12-31 0001637890 ifrs-full:Level2OfFairValueHierarchyMember cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2021-12-31 0001637890 ifrs-full:Level1OfFairValueHierarchyMember cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2021-12-31 0001637890 ifrs-full:AtFairValueMember 2021-12-31 0001637890 ifrs-full:OtherIntangibleAssetsMember 2021-12-31 0001637890 cyad:PatentsAndLicencesMember 2021-12-31 0001637890 ifrs-full:GoodwillMember 2021-12-31 0001637890 cyad:CathezDevelopmentCostsMember 2021-12-31 0001637890 cyad:OnCyteIprdMember 2021-12-31 0001637890 ifrs-full:ContingentConsiderationMember 2021-12-31 0001637890 cyad:LicenseAndCollaborationAgreementsMember cyad:MesoblastMember 2021-12-31 0001637890 cyad:OtherIncomeMember 2022-01-01 2022-06-30 0001637890 ifrs-full:ContingentConsiderationMember 2022-01-01 2022-06-30 0001637890 cyad:PropertyMemberMember 2022-01-01 2022-06-30 0001637890 ifrs-full:VehiclesMember 2022-01-01 2022-06-30 0001637890 cyad:PlantAndEquipmentsMember 2022-01-01 2022-06-30 0001637890 cyad:CardiologyMember 2022-01-01 2022-06-30 0001637890 cyad:ImmunoOncologyMember 2022-01-01 2022-06-30 0001637890 cyad:PropertyMember ifrs-full:GrossCarryingAmountMember 2022-01-01 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-01-01 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember cyad:PlantAndEquipmentsMember 2022-01-01 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember 2022-01-01 2022-06-30 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PropertyMember 2022-01-01 2022-06-30 0001637890 ifrs-full:AccumulatedImpairmentMember ifrs-full:VehiclesMember 2022-01-01 2022-06-30 0001637890 cyad:PlantAndEquipmentsMember ifrs-full:AccumulatedImpairmentMember 2022-01-01 2022-06-30 0001637890 ifrs-full:AccumulatedImpairmentMember 2022-01-01 2022-06-30 0001637890 cyad:CorporateMember 2022-01-01 2022-06-30 0001637890 ifrs-full:OtherReservesMember 2022-01-01 2022-06-30 0001637890 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001637890 cyad:WalloonRegionMember 2022-01-01 2022-06-30 0001637890 ifrs-full:AtFairValueMember 2022-01-01 2022-06-30 0001637890 cyad:PhaseOneToTwoMember cyad:CyadOneZeroTwoMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroTwoMember cyad:PhaseTwoToThreeMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroTwoMember cyad:PhaseThreeToBLAMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroTwoMember cyad:BLAToApprovalMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroTwoMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroTwoMember cyad:PhaseOneMember 2022-01-01 2022-06-30 0001637890 cyad:PhaseOneMember cyad:CyadOneZeroOneMember 2022-01-01 2022-06-30 0001637890 cyad:PhaseOneToTwoMember cyad:CyadOneZeroOneMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroOneMember cyad:PhaseTwoToThreeMember 2022-01-01 2022-06-30 0001637890 cyad:PhaseThreeToBLAMember cyad:CyadOneZeroOneMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroOneMember cyad:BLAToApprovalMember 2022-01-01 2022-06-30 0001637890 cyad:CyadOneZeroOneMember 2022-01-01 2022-06-30 0001637890 cyad:BoardOfDirectorMember 2022-01-01 2022-06-30 0001637890 cyad:ExecutiveManagementMember 2022-01-01 2022-06-30 0001637890 ifrs-full:LeaseLiabilitiesMember 2022-01-01 2022-06-30 0001637890 cyad:FederalBelgianInstituteForHealthInsuranceInamiMember 2022-01-01 2022-06-30 0001637890 cyad:AmlAndMdsFranchiseMember 2022-01-01 2022-06-30 0001637890 cyad:ResearchAndDevelopmentMember 2022-01-01 2022-06-30 0001637890 cyad:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2022-01-01 2022-06-30 0001637890 cyad:RecoverableCashAdvancesMember 2022-01-01 2022-06-30 0001637890 cyad:OtherExpensesMember 2022-01-01 2022-06-30 0001637890 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001637890 ifrs-full:CapitalRedemptionReserveMember 2022-01-01 2022-06-30 0001637890 cyad:OtherIncomeMember 2021-01-01 2021-06-30 0001637890 cyad:PropertyMemberMember 2021-01-01 2021-06-30 0001637890 ifrs-full:VehiclesMember 2021-01-01 2021-06-30 0001637890 cyad:PlantAndEquipmentsMember 2021-01-01 2021-06-30 0001637890 ifrs-full:IssuedCapitalMember 2021-01-01 2021-06-30 0001637890 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001637890 cyad:CardiologyMember 2021-01-01 2021-06-30 0001637890 cyad:ImmunoOncologyMember 2021-01-01 2021-06-30 0001637890 cyad:CorporateMember 2021-01-01 2021-06-30 0001637890 ifrs-full:OtherReservesMember 2021-01-01 2021-06-30 0001637890 ifrs-full:CapitalRedemptionReserveMember 2021-01-01 2021-06-30 0001637890 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001637890 cyad:BoardOfDirectorMember 2021-01-01 2021-06-30 0001637890 cyad:ExecutiveManagementMember 2021-01-01 2021-06-30 0001637890 cyad:AmlAndMdsFranchiseMember 2021-01-01 2021-06-30 0001637890 cyad:WalloonRegionMember 2021-01-01 2021-06-30 0001637890 ifrs-full:ContingentConsiderationMember 2021-01-01 2021-06-30 0001637890 cyad:OtherExpensesMember 2021-01-01 2021-06-30 0001637890 ifrs-full:IssuedCapitalMember 2021-07-01 2021-12-31 0001637890 ifrs-full:SharePremiumMember 2021-07-01 2021-12-31 0001637890 ifrs-full:OtherReservesMember 2021-07-01 2021-12-31 0001637890 ifrs-full:CapitalRedemptionReserveMember 2021-07-01 2021-12-31 0001637890 ifrs-full:RetainedEarningsMember 2021-07-01 2021-12-31 0001637890 ifrs-full:ContingentConsiderationMember 2021-01-01 2021-12-31 0001637890 cyad:PropertyMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2021-01-01 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember cyad:PlantAndEquipmentsMember 2021-01-01 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PropertyMember 2021-01-01 2021-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember ifrs-full:VehiclesMember 2021-01-01 2021-12-31 0001637890 cyad:PlantAndEquipmentsMember ifrs-full:AccumulatedImpairmentMember 2021-01-01 2021-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember 2021-01-01 2021-12-31 0001637890 ifrs-full:AtFairValueMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseOneMember cyad:CyadOneZeroTwoMember 2021-01-01 2021-12-31 0001637890 cyad:CyadOneZeroTwoMember cyad:PhaseOneToTwoMember 2021-01-01 2021-12-31 0001637890 cyad:CyadOneZeroTwoMember cyad:PhaseTwoToThreeMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseThreeToBLAMember cyad:CyadOneZeroTwoMember 2021-01-01 2021-12-31 0001637890 cyad:CyadOneZeroTwoMember cyad:BLAToApprovalMember 2021-01-01 2021-12-31 0001637890 cyad:CyadOneZeroTwoMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseOneMember cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseOneToTwoMember cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseTwoToThreeMember cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 cyad:PhaseThreeToBLAMember cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 cyad:BLAToApprovalMember cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 cyad:CyadOneZeroOneMember 2021-01-01 2021-12-31 0001637890 ifrs-full:SharePremiumMember 2021-05-25 2021-05-25 0001637890 cyad:AmendmentEnteredWithMesoblastToConvertTheLicenseIntoNonExclusiveMember cyad:MesoblastLicenseAgreementMember 2022-01-17 2022-01-17 0001637890 cyad:MesoblastLicenseAgreementMember 2022-01-17 2022-01-17 0001637890 cyad:MesoblastLicenseAgreementMember cyad:AmendmentEnteredWithMesoblastToConvertTheLicenseIntoNonExclusiveMember 2022-01-17 0001637890 ifrs-full:IssuedCapitalMember 2021-12-31 0001637890 ifrs-full:SharePremiumMember 2021-12-31 0001637890 ifrs-full:OtherReservesMember 2021-12-31 0001637890 ifrs-full:CapitalRedemptionReserveMember 2021-12-31 0001637890 ifrs-full:RetainedEarningsMember 2021-12-31 0001637890 ifrs-full:IssuedCapitalMember 2022-06-30 0001637890 ifrs-full:SharePremiumMember 2022-06-30 0001637890 ifrs-full:OtherReservesMember 2022-06-30 0001637890 ifrs-full:RetainedEarningsMember 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember cyad:PlantAndEquipmentsMember 2022-06-30 0001637890 ifrs-full:VehiclesMember ifrs-full:AccumulatedImpairmentMember 2022-06-30 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PlantAndEquipmentsMember 2022-06-30 0001637890 ifrs-full:VehiclesMember 2022-06-30 0001637890 cyad:PlantAndEquipmentsMember 2022-06-30 0001637890 cyad:PropertyMember ifrs-full:GrossCarryingAmountMember 2022-06-30 0001637890 ifrs-full:GrossCarryingAmountMember 2022-06-30 0001637890 cyad:PropertyMember ifrs-full:AccumulatedImpairmentMember 2022-06-30 0001637890 ifrs-full:AccumulatedImpairmentMember 2022-06-30 0001637890 cyad:PropertyMember 2022-06-30 0001637890 ifrs-full:IssuedCapitalMember 2020-12-31 0001637890 ifrs-full:SharePremiumMember 2020-12-31 0001637890 ifrs-full:OtherReservesMember 2020-12-31 0001637890 ifrs-full:CapitalRedemptionReserveMember 2020-12-31 0001637890 ifrs-full:RetainedEarningsMember 2020-12-31 0001637890 ifrs-full:IssuedCapitalMember 2021-06-30 0001637890 ifrs-full:SharePremiumMember 2021-06-30 0001637890 ifrs-full:OtherReservesMember 2021-06-30 0001637890 ifrs-full:RetainedEarningsMember 2021-06-30 0001637890 ifrs-full:CapitalRedemptionReserveMember 2021-06-30 0001637890 ifrs-full:ContingentConsiderationMember 2020-12-31 0001637890 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2020-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PropertyMember 2020-12-31 0001637890 ifrs-full:VehiclesMember ifrs-full:AccumulatedImpairmentMember 2020-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PlantAndEquipmentsMember 2020-12-31 0001637890 cyad:PropertyMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001637890 cyad:PlantAndEquipmentsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001637890 ifrs-full:GrossCarryingAmountMember 2020-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember 2020-12-31 0001637890 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember cyad:PlantAndEquipmentsMember 2021-12-31 0001637890 ifrs-full:VehiclesMember ifrs-full:AccumulatedImpairmentMember 2021-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember cyad:PlantAndEquipmentsMember 2021-12-31 0001637890 ifrs-full:VehiclesMember 2021-12-31 0001637890 cyad:PlantAndEquipmentsMember 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember cyad:PropertyMember 2021-12-31 0001637890 ifrs-full:GrossCarryingAmountMember 2021-12-31 0001637890 cyad:PropertyMember ifrs-full:AccumulatedImpairmentMember 2021-12-31 0001637890 ifrs-full:AccumulatedImpairmentMember 2021-12-31 0001637890 cyad:PropertyMember 2021-12-31 iso4217:EUR xbrli:shares xbrli:pure cyad:Subsidiaries iso4217:EUR xbrli:shares cyad:Segment
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM
6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2022
Commission File Number:
001-37452
 
 
CELYAD ONCOLOGY SA
(Translation of registrant’s name into English)
 
 
Rue Edouard Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F  ☒            Form
40-F  ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7):  ☐
 
 
 
Celyad Oncology SA
Financial and Operating Results
On August 5, 2022, Celyad Oncology SA (the “
Company
”) issued a press release announcing its financial and operating results for the first half of 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and a copy of the Company’s interim financial report for the first half of 2022 is attached hereto as Exhibit 99.2. Exhibits 99.1 and 99.2 are incorporated herein by reference.
The information contained in this Current Report on Form
6-K,
including Exhibits 99.1 and 99.2, except for the quote of Michel Lussier contained in Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statements on Forms
F-3
(File
No. 333-248464)
and
S-8
(File
No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
CELYAD ONCOLOGY SA
Date: August 5, 2022
 
 
By:
 
/s/ Michel Lussier
 
 
 
Michel Lussier
 
 
 
Interim Chief Executive Officer
Celyad (CE) (USOTC:CLYYF)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024 Celyad (CE) 차트를 더 보려면 여기를 클릭.
Celyad (CE) (USOTC:CLYYF)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024 Celyad (CE) 차트를 더 보려면 여기를 클릭.